Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1354744-91-4
2. Nktr-118 Oxalate
3. Naloxegol (oxalate)
4. Naloxegol Oxalate [usan]
5. Az13337019 Oxalate
6. Az-13337019 Oxalate
7. 65i14tnm33
8. Moventig
9. (4r,4as,7s,7ar,12bs)-7-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;oxalic Acid
10. Naloxegol Oxalate (usan)
11. Unii-65i14tnm33
12. Movantik (tn)
13. Moventig (tn)
14. Nktr-118-oxalate
15. Naloxegol Oxalate [mi]
16. Naloxegol Oxalate(nktr-118)
17. Chembl2219416
18. Schembl20839999
19. Hy-a0118a
20. Dtxsid50159395
21. Naloxegol Oxalate [who-dd]
22. Akos030526444
23. Cs-5349
24. Naloxegol Oxalate [orange Book]
25. Nktr-118;az-13337019 Oxalate
26. Ac-36031
27. Movantik Component Naloxegol Oxalate
28. Az 13337019
29. Naloxegol Oxalate Component Of Movantik
30. D10375
31. Q27263878
32. 4,5.alpha.-epoxy-6.alpha.-((3,6,7,12,15,18,21-heptaoxadocosyl)oxy)-17-(prop-2-enyl)morphinan-3,14-diol Hydrogen Ethanedioate
33. 4,5alpha-epoxy-6alpha-((3,6,7,12,15,18,21-heptaoxadocosyl)oxy)-17-(prop-2-enyl)morphinan-3,14-diol Hydrogen Ethanedioate
34. Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)-, (5.alpha.,6.alpha.)-, Ethanedioate (1:1)
35. Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)-, (5alpha,6alpha)-, Ethanedioate (1:1)
| Molecular Weight | 741.8 g/mol |
|---|---|
| Molecular Formula | C36H55NO15 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 16 |
| Rotatable Bond Count | 25 |
| Exact Mass | 741.35717005 g/mol |
| Monoisotopic Mass | 741.35717005 g/mol |
| Topological Polar Surface Area | 201 Ų |
| Heavy Atom Count | 52 |
| Formal Charge | 0 |
| Complexity | 971 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
A06AH03
GDUFA
DMF Review : Complete
Rev. Date : 2019-01-29
Pay. Date : 2018-11-30
DMF Number : 33405
Submission : 2018-12-01
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2018-07-16
Pay. Date : 2018-04-04
DMF Number : 32562
Submission : 2018-03-21
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2018-06-19
Pay. Date : 2018-04-04
DMF Number : 32535
Submission : 2018-03-03
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Through the acquisition, Grunenthal will leverage the Valinor pipeline, which also includes Movantik (naloxegol), indicated for the treatment of OIC in adult patients with chronic non-cancer pain.
Lead Product(s): Naloxegol Oxalate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Movantik
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Grunenthal
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 22, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naloxegol Oxalate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Grunenthal
Deal Size : $250.0 million
Deal Type : Acquisition
Grünenthal Continues US Growth Push with $250M Acquisition of Valinor Pharma
Details : Through the acquisition, Grunenthal will leverage the Valinor pipeline, which also includes Movantik (naloxegol), indicated for the treatment of OIC in adult patients with chronic non-cancer pain.
Product Name : Movantik
Product Type : Controlled Substance
Upfront Cash : Undisclosed
July 22, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
MOVANTIK is the leading Peripherally-Acting Mu-Receptor Opioid antagonist (PAMORA) indicated for the treatment of opioid induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer.
Lead Product(s): Naloxegol Oxalate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Movantik
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: HCR
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 14, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naloxegol Oxalate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : HCR
Deal Size : Undisclosed
Deal Type : Agreement
Details : MOVANTIK is the leading Peripherally-Acting Mu-Receptor Opioid antagonist (PAMORA) indicated for the treatment of opioid induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior canc...
Product Name : Movantik
Product Type : Controlled Substance
Upfront Cash : Undisclosed
November 14, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placebo were evaluated across high and low opioid dosages.
Lead Product(s): Naloxegol Oxalate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Movantik
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 07, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naloxegol Oxalate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RedHill Biopharma Introduces Three New Movantik Data Analyzes at PAINWeek 2021
Details : Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placebo were evaluated across high and low opioid dosages.
Product Name : Movantik
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 07, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the terms of the settlement agreement, Apotex may not sell a generic version of Movantik in the U.S. until October 1, 2030 (subject to U.S. FDA approval) or earlier under certain circumstances.
Lead Product(s): Naloxegol Oxalate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Movantik
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Apotex Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 22, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naloxegol Oxalate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Apotex Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex
Details : Under the terms of the settlement agreement, Apotex may not sell a generic version of Movantik in the U.S. until October 1, 2030 (subject to U.S. FDA approval) or earlier under certain circumstances.
Product Name : Movantik
Product Type : Controlled Substance
Upfront Cash : Undisclosed
July 22, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Both analyses included pooled data from two large, robust, identically designed Phase 3 studies of Movantik (Kodiak 4 and Kodiak 5), involving 891 treated patients across two doses (12.5 mg and 25 mg), compared to a total of 546 patients in the placebo arms.
Lead Product(s): Naloxegol Oxalate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Movantik
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 24, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naloxegol Oxalate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Both analyses included pooled data from two large, robust, identically designed Phase 3 studies of Movantik (Kodiak 4 and Kodiak 5), involving 891 treated patients across two doses (12.5 mg and 25 mg), compared to a total of 546 patients in the placebo a...
Product Name : Movantik
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 24, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The agreements secure high-quality manufacturing capacity of Movantik® for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease.
Lead Product(s): Naloxegol Oxalate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Movantik
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: RedHill Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 18, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naloxegol Oxalate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : RedHill Biopharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : The agreements secure high-quality manufacturing capacity of Movantik® for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease.
Product Name : Movantik
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 18, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RedHill Biopharma has gained the rights to Movantik (naloxegol)1 in Israel from AstraZeneca. RedHill now holds the worldwide rights to Movantik, excluding Europe and Canada. RedHill to evaluate partnering opportunities for commercialization of Movantik in Israel.
Lead Product(s): Naloxegol Oxalate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Moventig
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: RedHill Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 08, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naloxegol Oxalate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : RedHill Biopharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
Details : RedHill Biopharma has gained the rights to Movantik (naloxegol)1 in Israel from AstraZeneca. RedHill now holds the worldwide rights to Movantik, excluding Europe and Canada. RedHill to evaluate partnering opportunities for commercialization of Movantik i...
Product Name : Moventig
Product Type : Controlled Substance
Upfront Cash : Undisclosed
October 08, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RedHill and Daiichi Sankyo replaced their co-commercialization agreement for Movantik® with a new royalty-bearing agreement, under which RedHill will maintain sole and exclusive responsibility for the commercialization of Movantik® in the U.S.
Lead Product(s): Naloxegol Oxalate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Movantik
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: RedHill Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 03, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naloxegol Oxalate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : RedHill Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®
Details : RedHill and Daiichi Sankyo replaced their co-commercialization agreement for Movantik® with a new royalty-bearing agreement, under which RedHill will maintain sole and exclusive responsibility for the commercialization of Movantik® in the U.S.
Product Name : Movantik
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 03, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which has now been transferred to RedHill.
Lead Product(s): Naloxegol Oxalate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Moventig
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: RedHill Biopharma
Deal Size: $67.5 million Upfront Cash: $52.5 million
Deal Type: Divestment April 02, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naloxegol Oxalate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : RedHill Biopharma
Deal Size : $67.5 million
Deal Type : Divestment
AZ licences Movantik rights to RedHill
Details : In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which has now been transferred to RedHill.
Product Name : Moventig
Product Type : Controlled Substance
Upfront Cash : $52.5 million
April 02, 2020

Details:
Naloxegol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Constipation.
Lead Product(s): Naloxegol Oxalate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 20, 2017

Lead Product(s) : Naloxegol Oxalate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Naloxegol and Opioid-induced Constipation
Details : Naloxegol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2017

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
19
PharmaCompass offers a list of Naloxegol Oxalate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Naloxegol Oxalate manufacturer or Naloxegol Oxalate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Naloxegol Oxalate manufacturer or Naloxegol Oxalate supplier.
PharmaCompass also assists you with knowing the Naloxegol Oxalate API Price utilized in the formulation of products. Naloxegol Oxalate API Price is not always fixed or binding as the Naloxegol Oxalate Price is obtained through a variety of data sources. The Naloxegol Oxalate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Naloxegol Oxalate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Naloxegol Oxalate, including repackagers and relabelers. The FDA regulates Naloxegol Oxalate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Naloxegol Oxalate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Naloxegol Oxalate supplier is an individual or a company that provides Naloxegol Oxalate active pharmaceutical ingredient (API) or Naloxegol Oxalate finished formulations upon request. The Naloxegol Oxalate suppliers may include Naloxegol Oxalate API manufacturers, exporters, distributors and traders.
click here to find a list of Naloxegol Oxalate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Naloxegol Oxalate DMF (Drug Master File) is a document detailing the whole manufacturing process of Naloxegol Oxalate active pharmaceutical ingredient (API) in detail. Different forms of Naloxegol Oxalate DMFs exist exist since differing nations have different regulations, such as Naloxegol Oxalate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Naloxegol Oxalate DMF submitted to regulatory agencies in the US is known as a USDMF. Naloxegol Oxalate USDMF includes data on Naloxegol Oxalate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Naloxegol Oxalate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Naloxegol Oxalate suppliers with USDMF on PharmaCompass.
A Naloxegol Oxalate written confirmation (Naloxegol Oxalate WC) is an official document issued by a regulatory agency to a Naloxegol Oxalate manufacturer, verifying that the manufacturing facility of a Naloxegol Oxalate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Naloxegol Oxalate APIs or Naloxegol Oxalate finished pharmaceutical products to another nation, regulatory agencies frequently require a Naloxegol Oxalate WC (written confirmation) as part of the regulatory process.
click here to find a list of Naloxegol Oxalate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Naloxegol Oxalate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Naloxegol Oxalate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Naloxegol Oxalate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Naloxegol Oxalate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Naloxegol Oxalate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Naloxegol Oxalate suppliers with NDC on PharmaCompass.
Naloxegol Oxalate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Naloxegol Oxalate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Naloxegol Oxalate GMP manufacturer or Naloxegol Oxalate GMP API supplier for your needs.
A Naloxegol Oxalate CoA (Certificate of Analysis) is a formal document that attests to Naloxegol Oxalate's compliance with Naloxegol Oxalate specifications and serves as a tool for batch-level quality control.
Naloxegol Oxalate CoA mostly includes findings from lab analyses of a specific batch. For each Naloxegol Oxalate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Naloxegol Oxalate may be tested according to a variety of international standards, such as European Pharmacopoeia (Naloxegol Oxalate EP), Naloxegol Oxalate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Naloxegol Oxalate USP).